EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity

EnteroMedics Inc.

, the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has completed enrollment and device implantation in the Company's ReCharge pivotal trial for obesity. A total of 233 patients have been successfully implanted at 10 clinical sites in the U.S. and Australia. The ReCharge trial is a randomized, double-blind, parallel-group, multicenter pivotal study testing the effectiveness and safety of VBLOC® vagal blocking therapy, delivered via EnteroMedics' Maestro® Rechargeable System, in the treatment of obesity. VBLOC Therapy is a first-in-class weight loss treatment which is designed to control both hunger and fullness by regulating the primary nerve which controls the digestive system. It is designed to be minimally invasive and to address the lifelong challenge of obesity by empowering the individual to take positive steps along a path toward weight loss without compromising their anatomy or lifestyle. The Company also announced that in addition to receiving the previously announced initial approvals for the critical active implantable medical device (AIMD) components of the Maestro System by the Therapeutic Goods Administration (

) for the listing on the Australian Register of Therapeutic Goods (

), EnteroMedics has also received approval for six of the eight remaining individual class III components.